MeiraGTx Holdings plc
$7.98-$0.16 (-2.0%)
Last close · Data as of Nov 20, 2026
- Market cap
- $886.3M
- P/E
- -7.8x
- EV / EBITDA
- -10.2x
- Revenue
- $81.4M
- Net margin
- -140.3%
- ROCE
- -86.9%
Price chart
Technical chartScreen technicals →+7.4% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- -20.0%
- 3M
- -45.1%
- 6M
- -16.7%
- 1Y
- +7.4%
- 5Y
- -57.2%
52-week range
Day change -$0.16 (-2.0%) from $8.14 to $7.98 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in MGTX, bought on each weekday since 2021.
News & filings
What MeiraGTx Holdings filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockConcernShareholders' equity is negative: liabilities exceed assets.
Strengths (1)
- Revenue more than doubled in fiscal 2025.
- The stored ratios (as of 11 Jun 2026) describe a profitable period while fiscal 2025 shows a net loss: the two cover different periods, so the ratio points are not shown.
- Shareholders' equity is negative, so return on equity and debt to equity are not shown.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia.
Read moreShow less
MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also develops AAV-AQP1 for radiation-induced grade 2/3 radiation-induced xerostomia, as well as for Sjogren's syndrome; AAV-GAD in Phase 2 trial for Parkinson's disease; AAV-RPE65 in Phase 2 trial for RPE65-associated retinal dystrophy; and AAV-CNGB3 and AAV-CNGA3, which are both in Phase ½ clinical trial for achromatopsia, as well as offers AAV-AIPL1 for Leber congenital amaurosis (LCA) 4. In addition, the company's products under preclinical development include AAV-RDH12 for retinol dehydrogenase 12 mutation-associated retinal dystrophy; AAV-BBS10 for Bardet-Biedl syndrome (BBS) due to BBS10 mutations; AAV-RetGC for LCA type 1; and AAV-UPF1 for amyotrophic lateral sclerosis, as well as programs for Alzheimer's disease, and wet and dry neovascular age related macular degeneration. Further, it provides riboswitch platform for the delivery of metabolic peptides; and cell therapies for oncology, autoimmune disease, and long term intractable pain. The company has collaborations with Johnson & Johnson Innovative Medicine for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease; and Hologen Limited for the research, development, manufacture, and commercialization of AAV-GAD investigational gene therapy for the treatment of Parkinson's disease, AAV-BDNF investigational gene therapy for genetic obesity disorders, and other genetic medicines to the central nervous system. MeiraGTx Holdings plc was founded in 2015 and is based in New York, New York.
- Sector
- Healthcare
- Shares outstanding
- 81.1M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $886.3M
- P/E
- -7.8x
- P/B
- -153.0x
- EV / EBITDA
- -10.2x
- EV / Sales
- 11.2x
- P/S
- 10.9x
- 52-week high
- $14.97
- 52-week low
- $6.99
Profitability
- Operating margin
- -130.2%
- Net margin
- -140.3%
- EBITDA margin
- -109.8%
- ROE
- 1971.4%
- ROCE
- -86.9%
- ROIC
- -475.1%
- ROA
- -46.7%
- Asset turnover
- 0.33
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $81.4M
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 144.6%
- Revenue CAGR, 3YFY2025, the latest fiscal year in the company's growth history.
- 72.3%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- -22.7%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- -$50.6M
Solvency
- Current ratio
- 0.75
- Debt / Equity
- -15.31
- Debt / Assets
- 0.36
- CFO / Net profit
- 0.41
- Cash / Market cap
- 7.4%
Where the revenue went
FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.
| Line | FY2025 |
|---|---|
| Revenue | $81.4M |
| Cost of revenue | $4.8M |
| Gross profit | $76.5M |
| Operating expenses | $182.5M |
| Research and development | $129.6M |
| Selling, general and administrative | $52.9M |
| Operating income | -$106.0M |
| Interest and other | -$8.2M |
| Pretax income | -$114.2M |
| Tax and other | $0.00 |
| Net income | -$114.2M |
Revenue and net profit
Revenue grew 144.6% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $15.9M | -$129.6M |
| FY2023 | $14.0M | -$84.0M |
| FY2024 | $33.3M | -$147.8M |
| FY2025 | $81.4M | -$114.2M |
Cash flows
FY2025: -$46.4M from operations, -$50.6M free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | -$73.1M | -$118.1M |
| FY2023 | -$105.4M | -$125.5M |
| FY2024 | -$104.5M | -$109.5M |
| FY2025 | -$46.4M | -$50.6M |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $81.4M+144.6%1Y
- EBITDA
- -$89.4M
- Net profit
- -$114.2M
- Cash from operations
- -$46.4M
- Free cash flow
- -$50.6M
- Revenue CAGR, 3Y
- 72.3%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $81.4M | -$89.4M | -$114.2M | -$50.6M | 1971.4% | +144.6% | -22.7% |
Monthly returns
Month-by-month returns of MGTX across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $244.4M |
| Current assets | $91.8M |
| Non-current assets | $152.7M |
| Liabilities | $250.2M |
| Current liabilities | $122.6M |
| Non-current liabilities | $127.7M |
| Equity | -$5.8M |
| Paid-in capital | $808.0M |
| Retained earnings | -$816.2M |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; MGTX highlighted.
P/E against peers
Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.
Not shown (no positive earnings and no EV / Sales): Annexon, Inc., Cullinan Therapeutics, Inc., Jade Biosciences, Inc.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| MeiraGTx Holdings plcMGTXthis company | $886.3M | -7.8x | -153.0x | 1971.4% | -10.2x |
| ARS Pharmaceuticals, Inc.SPRY | $900.7M | -5.3x | 7.9x | -149.9% | -5.7x |
| Annexon, Inc.ANNX | $892.9M | -4.3x | 4.2x | -97.7% | -3.5x |
| Pacira BioSciences, Inc.PCRX | $892.0M | 126.9x | 1.3x | 1.0% | 8.7x |
| Xencor, Inc.XNCR | $890.4M | — | 1.4x | -14.5% | — |
| Cullinan Therapeutics, Inc.CGEM | $886.8M | -4.0x | 2.2x | -53.8% | -3.3x |
| Jade Biosciences, Inc.JBIO | $875.6M | — | -18.7x | -38.3% | — |
| Certara, Inc.CERT | $872.7M | -547.2x | 0.8x | -0.2% | 9.7x |
| Talkspace, Inc.TALK | $871.1M | 111.8x | 7.4x | 6.7% | 129.1x |
| Peer median | — | -4.2x | 1.8x | -26.4% | 2.7x |
Year-to-date ROI
MGTX since 1 January, against earlier years.
Historical volatility
MGTX's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2022 | -730.9% |
| FY2023 | -977.6% |
| FY2024 | -493.4% |
| FY2025 | -130.2% |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $81.4M |
| Cost of revenueCost Of Revenue | $4.8M |
| Gross profitGross Profit | $76.5M |
| Operating expensesOperating Expense | $182.5M |
| Research and developmentResearch And Development | $129.6M |
| Selling, general and administrativeSelling General And Administration | $52.9M |
| Total expensesTotal Expenses | $187.4M |
| Operating incomeOperating Income | -$106.0M |
| Interest and other | |
| Pretax incomePretax Income | -$114.2M |
| Tax | |
| Net incomeNet Income | -$114.2M |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $244.4M |
| Current assetsCurrent Assets | $91.8M |
| Non-current assetsTotal Non Current Assets | $152.7M |
| LiabilitiesTotal Liabilities Net Minority Interest | $250.2M |
| Current liabilitiesCurrent Liabilities | $122.6M |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $127.7M |
| EquityTotal Equity Gross Minority Interest | -$5.8M |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | -$46.4M |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | -$46.3M |
| Net income, continuing operationsNet Income From Continuing Operations | -$114.2M |
| Depreciation and amortisationDepreciation And Amortization | $12.6M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $12.6M |
| Depreciation | $12.3M |
| Amortization cash flowAmortization Cash Flow | $300.0k |
| Amortization of intangiblesAmortization Of Intangibles | $300.0k |
| Stock-based compensationStock Based Compensation | $22.1M |
| Operating gains and lossesOperating Gains Losses | -$1.8M |
| Gain loss on sale of PP&EGain Loss On Sale Of PPE | $360.0k |
| Net foreign currency exchange gain lossNet Foreign Currency Exchange Gain Loss | -$2.1M |
| Earnings losses from equity investmentsEarnings Losses From Equity Investments | $0.00 |
| Asset impairmentAsset Impairment Charge | — |
| Change in working capitalChange In Working Capital | $28.0M |
| Other non-cash itemsOther Non Cash Items | $6.9M |
| Investing cash flowInvesting Cash Flow | -$4.1M |
| Cash from continuing investingCash Flow From Continuing Investing Activities | -$4.1M |
| Capital expenditureCapital Expenditure | -$4.2M |
| Purchase of PP&EPurchase Of PPE | -$3.8M |
| Sale of PP&ESale Of PPE | $130.0k |
| Net PP&E purchases and salesNet PPE Purchase And Sale | -$3.7M |
| AcquisitionsPurchase Of Business | — |
| Net acquisitions and disposalsNet Business Purchase And Sale | — |
| Purchase of intangiblesPurchase Of Intangibles | -$410.0k |
| Sale of intangiblesSale Of Intangibles | — |
| Net intangibles purchases and salesNet Intangibles Purchase And Sale | -$410.0k |
| Other investing changesNet Other Investing Changes | — |
| Financing cash flowFinancing Cash Flow | $12.3M |
| Cash from continuing financingCash Flow From Continuing Financing Activities | $12.3M |
| Debt issuedIssuance Of Debt | — |
| Debt repaidRepayment Of Debt | -$30.0k |
| Net debt issuedNet Issuance Payments Of Debt | -$30.0k |
| Short-term debt issuedShort Term Debt Issuance | — |
| Net short-term debt issuedNet Short Term Debt Issuance | — |
| Long-term debt issuedLong Term Debt Issuance | — |
| Long-term debt repaidLong Term Debt Payments | -$30.0k |
| Net long-term debt issuedNet Long Term Debt Issuance | -$30.0k |
| Shares issuedIssuance Of Capital Stock | $15.1M |
| Common stock issuedCommon Stock Issuance | $15.1M |
| Net common stock issuedNet Common Stock Issuance | $15.1M |
| Stock options exercisedProceeds From Stock Option Exercised | $260.0k |
| Dividends paidCash Dividends Paid | — |
| Other financing chargesNet Other Financing Charges | -$3.0M |
| Interest paid (financing)Interest Paid Cff | — |
| Change in cashChanges In Cash | -$38.2M |
| Effect of exchange ratesEffect Of Exchange Rate Changes | 72.0% |
| Cash at the start of the yearBeginning Cash Position | $105.7M |
| Cash at the end of the yearEnd Cash Position | $68.2M |
| Free cash flowFree Cash Flow | -$50.6M |
| Supplemental |
Learn while you research
Academy chapters picked for MeiraGTx Holdings plc and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Growth Investing145% revenue growth is in the top tier, learn how to value growth.7 min read
- 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read